期刊文献+

23例抗反转录病毒治疗引起脂肪增生临床特点 被引量:1

Clinical characteristics of 23 cases of lipidosis induced by antiretroviral therapy
暂未订购
导出
摘要 目的探讨抗反转录病毒治疗(ART)引起脂肪增生的临床特点。方法选择该院2017年1月至2018年6月住院发生的ART后脂肪增生患者23例,就诱导药物、临床表现、危险因素和治疗等进行分析。结果常见的药物为司他夫定、拉米夫定和洛匹那韦利托那韦;主要表现为项背部脂肪增生,进行性增大,23例脂肪增生患者中17例(73.91%)表现为项背部脂肪异常增生,3例(13.04%)背部肿物,乳房脂肪增生、腋窝脂肪增生及双上肢数个脂肪瘤各1例(4.35%);23例患者中合并2型糖尿病6例(26.09%)、高血压6例(26.09%)、脂肪肝5例(21.74%)、高脂血症5例(21.74%)。大部分经过对症治疗后病情稳定;2例(8.70%)复发,分别于3、4年后行二次手术治疗。结论长期ART后可出现脂肪增生,在其治疗过程中应定期监测患者血脂、血糖水平。 Objective To analyze the clinical characteristics of lipidosis caused by antiretroviral therapy(ART).Methods 23 patients with lipidosis from January 2017 to June 2018 were collected which were analyzed for related drugs,clinical manifestations,risk factors and treatments.Results The common drugs were Stavudine,lamivudine and lopinavirinadone;mainly manifested as the back fat hyperplasia,progressive enlargement,of 23 patients with fat hyperplasia 17 cases(73.91%)showed abnormal hyperplasia of the back,3 cases(13.04%)of back mass,breast fat hyperplasia,axillary fat hyperplasia and several upper lip muscles 1 case(4.35%)each;6 cases(26.09%)of type 2 diabetes,6 cases(26.09%)of hypertension,5 cases(21.74%)of fatty liver,5 cases(21.74%)of hyperlipidemia.Most of them were stable after symptomatic treatment;2 cases(8.70%)of recurrence,secondary surgery after 3 and 4 years respectively.Conclusion Lipidosis will occurs after long-term ART.Blood lipid and blood glucose levels should be monitored regularly during the treatment.
作者 夏玉朝 薛晓拉 杨萱 杨少杰 安永辉 XIA Yuchao;XUE Xiaola;YANG Xuan;YANG Shaojie;AN Yonghui(Department of Pharmacy,Zhengzhou SixthPeople's Hospital,Zhengzhou,Henan 45000,China;Department of Infection,Zhengzhou SixthPeople's Hospital,Zhengzhou,Henan 45000,China)
出处 《重庆医学》 CAS 2019年第9期1520-1522,共3页 Chongqing medicine
基金 国家"十二五"科技重大专项(2012ZX10001003) 河南省郑州市科技攻关项目(153PKJGG076)
关键词 脂肪增生 临床特点 抗反转录病毒治疗 adipose hyperplasia clinical features anti-retroviral therapy
  • 相关文献

参考文献2

二级参考文献14

  • 1Cherry CL,Nolan D,James IR,et al.Tissue-specific associa-tions between mitochondrial DNA levels and current treatmentstatus in HIV-infected individuals[J] .J Acquir Immune DeficSyndr,2006,42(4):435-440.
  • 2Raboud JM,Diong C,Carr A,et al.A meta-analysis of sixplacebo-controlled trials of thiazolidinedione therapy for HIVlipoatrophy[J] .HIV Clin Trials,2010,11(1):39-50.
  • 3A Calmy,M Bloch,H Wand,et al.No significant effect of uri-dine or pravastatin treatment for HIV lipoatrophy in men whohave ceased thymidine analogue nucleoside reverse transcrip-tase inhibitor therapy:a randomized trial[J] .HIV Med,2010,11(8):493-501.
  • 4McComsey GA,Walker UA,Budhathoki CB,et al.Uridinesupplementation in the treatment of HIV lipoatrophy:resultsof ACTG 5229[J] .AIDS,2010,24(16):2507-2515.
  • 5Guaraldi G,De Fazio D,Orlando G,et al.Facial lipohyper-trophy in HIV-infected subjects who underwent autologousfat tissue transplantation[J] .Clin Infect Dis,2005,40(2):e13–e15.
  • 6Scherzer R,Heymsfield SB,Lee D,et al.Decreased limb mus-cle and increased central adiposity are associated with 5-yearall-cause mortality in HIV infection[J] .AIDS,2011,25(11):1405–1414.
  • 7Falutz J,Allas S,Blot K,et al.Metabolic effects of a growthhormone-releasing factor in patients with HIV[J] .N Engl JMed,2007,357(23):2359-2370.
  • 8Negredo E,MoltóJ,Puig J,et al.Ezetimibe,a promising lip-id-lowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statins[J] .AIDS,2006,20(17):2159-64.
  • 9Brown TT,Cole SR,Li X,et al.Antiretroviral therapy andthe prevalence and incidence of diabetes mellitus in the multi-center AIDS cohort study[J] .Arch Intern Med,2005,165(10):1179-1184.
  • 10Hadigan C,Rabe J,Grinspoon S.Sustained benefits of met-formin therapy on markers of cardiovascular risk in humanimmunodeficiency virus-infected patients with fat redistribu-tion and insulin resistance[J] .J Clin Endocrinol Metab,2002,87(10):4611-4615.

共引文献7

同被引文献23

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部